Skip to main content

Advertisement

Fig. 2 | BMC Cancer

Fig. 2

From: Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study

Fig. 2

Clonigenicity inhibition of Cisplatin (IV) prodrugs. Cancer cells A2780 (a, b), A2780cisR (a, c) and HT29 (a, d) were grown on soft agar and treated with 5, 0.5 and 0.05 microM of Cisplatin, Oxaliplatin, RJY6, RJY9, RJY11 and RJY13 or solvent-treated cells (a) according to Materials and Methods. e IC50s values of clonigenicity inhibition of the different derivatives are in nM. Data shown are of representative experiment with coefficient of variation (CV) below 15 % in all samples. Experiment was repeated three times with comparable outcome

Back to article page